DHG Pharmaceutical JSC (HOSE:DHG)

DHG Pharmaceutical JSC Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	4,820,894	4,884,868	5,015,395	4,676,016	4,003,170	3,755,619
Revenue Growth (YoY)	-4.45%	-2.60%	7.26%	16.81%	6.59%	-3.62%
Cost of Revenue	2,628,239	2,747,102	2,671,850	2,418,521	2,082,260	1,944,243
Gross Profit	2,192,655	2,137,766	2,343,545	2,257,495	1,920,911	1,811,376
Selling, General & Admin	1,219,289	1,217,491	1,291,264	1,181,417	1,060,127	1,002,160
Operating Expenses	1,219,289	1,217,491	1,291,264	1,181,417	1,060,127	1,002,160
Operating Income	973,366	920,276	1,052,281	1,076,078	860,784	809,216
Interest Expense	-25,802	-24,811	-29,530	-12,559	-12,080	-14,030
Interest & Investment Income	131,013	138,160	202,173	120,337	114,306	133,858
Earnings From Equity Investments	-	-	-	-	-	-500.64
Currency Exchange Gain (Loss)	-2,225	-2,514	5,580	3,587	4,160	-2,966
Other Non Operating Income (Expenses)	-129,247	-127,857	-73,082	-89,517	-93,955	-84,764
EBT Excluding Unusual Items	947,104	903,254	1,157,423	1,097,926	873,214	840,814
Gain (Loss) on Sale of Investments	140	262.5	315	-772.55	274.7	-14,605
Gain (Loss) on Sale of Assets	415.61	967.73	1,437	2,518	-7,999	3,264
Asset Writedown	-	-	-	-	-	-3,011
Other Unusual Items	-	-	-	-58.33	-1,488	-5,438
Pretax Income	947,660	904,485	1,159,174	1,099,613	864,002	821,024
Income Tax Expense	124,729	125,564	108,512	111,159	87,717	82,490
Earnings From Continuing Operations	822,931	778,920	1,050,663	988,455	776,285	738,534
Minority Interest in Earnings	-	-	-	-	934.93	1,341
Net Income	822,931	778,920	1,050,663	988,455	777,220	739,875
Preferred Dividends & Other Adjustments	26,688	25,368	33,520	31,654	29,317	28,196
Net Income to Common	796,243	753,553	1,017,143	956,801	747,903	711,679
Net Income Growth	-9.76%	-25.86%	6.29%	27.18%	5.05%	16.45%
Shares Outstanding (Basic)	131	131	131	131	131	131
Shares Outstanding (Diluted)	131	131	131	131	131	131
Shares Change (YoY)	-0.81%	-	-	-	-	-
EPS (Basic)	6090.00	5763.48	7779.53	7318.01	5720.27	5443.21
EPS (Diluted)	6089.52	5763.00	7779.53	7318.01	5720.27	5443.21
EPS Growth	-9.90%	-25.92%	6.31%	27.93%	5.09%	16.61%
Free Cash Flow	1,220,030	1,228,879	-246,171	667,293	427,882	737,369
Free Cash Flow Per Share	9331.29	9398.97	-1882.82	5103.73	3272.62	5639.70
Dividend Per Share	-	-	7500.000	3500.000	3500.000	4000.000
Dividend Growth	-	-	114.29%	-	-12.50%	-
Gross Margin	45.48%	43.76%	46.73%	48.28%	47.98%	48.23%
Operating Margin	20.19%	18.84%	20.98%	23.01%	21.50%	21.55%
Profit Margin	16.52%	15.43%	20.28%	20.46%	18.68%	18.95%
Free Cash Flow Margin	25.31%	25.16%	-4.91%	14.27%	10.69%	19.63%
EBITDA	1,147,738	1,088,924	1,140,985	1,157,079	943,348	897,413
EBITDA Margin	23.81%	22.29%	22.75%	24.75%	23.57%	23.89%
D&A For EBITDA	174,373	168,648	88,704	81,001	82,564	88,197
EBIT	973,366	920,276	1,052,281	1,076,078	860,784	809,216
EBIT Margin	20.19%	18.84%	20.98%	23.01%	21.50%	21.55%
Effective Tax Rate	13.16%	13.88%	9.36%	10.11%	10.15%	10.05%
Revenue as Reported	4,820,894	4,884,868	5,015,395	4,676,016	4,003,170	3,755,619
Advertising Expenses	-	61,742	128,162	138,011	138,095	119,136

Source: S&P Global Market Intelligence. Standard template. Financial Sources.